Yan Xie, Yuqin Song and Jun Zhu*
Relapsed/refractory (r/r) Mantle Cell Lymphoma (MCL) is a subtype of mature B-cell lymphoma and characterized by heterogenous and aggressive clinical behaviors. Patients treated with conventional agents have a poor prognosis, especially those who have failed BTKi treatment, indicating a high unmet need for novel therapies. Chimeric Antigen Receptor (CAR) T-cell therapy has been approved for the treatment of r/r hematologic malignancies. In this case, we present a patient with MCL who exhibited many poor risk features, such as a high tumor burden with a Sum of Product of Diameters (SPD) of 19124 mm2, serous cavity effusion, and extensive treatment with systematic therapies. After failing multiple lines of systemic chemotherapies, autologous stem-cell transplantation, and treatment with the BTK inhibitor (ibrutinib), the patient received a single dose of 100 × 106 CAR+ T cells of relma-cel, a cellular therapy comprising autologous T cells transduced with an anti-CD19 chimeric antigen receptor. The patient responded to the relma-cel treatment with a long-term and sustainable Complete Response (CR), which persisted until the end of the 2-year follow-up period. Our findings confirmed the therapeutic benefit of relma-cel in r/r MCL patients with high-risk features.